Lassa Viral Transmission and Immunoprotection: Defective Interfering Particles (DIPs) in Carrier Rodents and Lassa Virus-Infected People
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 473816
Grant search
Key facts
Disease
Lassa Haemorrhagic Feverstart year
2022Known Financial Commitments (USD)
$109,655.17Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Nadesalingam AngaleeResearch Location
BelizeLead Research Institution
Broad Institute of MIT and Harvard (Cambridge, MA)Research Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The World Health Organization lists Lassa virus (LASV) as one of the of top 10 pathogens with high epidemic potential. LASV is currently endemic to West Africa, infecting up to 500,000 people, annually. It causes Lassa fever (LF) with symptoms ranging from malaise/deafness to haemorrhaging through all orifices. LASV can be as dangerous as Ebola and SARS-CoV-2. About 20% of LASV-infected people develop disease that can severely damage the brain, liver, spleen, kidney and other vital organs. Hospital fatality of LF patients can be as high as 69%. But, the reasons why LASV-infected people mount such varying immune responses are not understood. LASV is transmitted to humans mainly through the aerosols of urine/faeces of rodents. As an RNA virus, it has an inaccurate system of replication. 'Errors' in replication can lead to the production of defective interfering viral particles (DIPs) that are known to modulate immune response, in other RNA viruses. DIPs are present in LASV-infected mice, but their relevance in LF in humans is unknown. Therefore, during my Fellowship, I will determine whether (i) DIP levels vary between rodent species and modify transmissibility to humans, and how (ii) DIPs modulate immune responses in LASV-infected people, and regulate disease severity in LF patients. DIPs will be measured in rodent urine, faeces and tissue to understand how individuals in endemic areas are exposed to Lassa antigens. DIPs and antibodies in the patients' blood will be studied to reveal their role in disease progression and immunity. Because DIPs stimulate immune response without causing infection, DIPs are considered as vaccine candidates (e.g., Ebola, SARS-CoV-2, Dengue, Zika). No satisfactory treatment or vaccine is available to fight against LF. Hence, understanding LASV transmission and immunogenicity via a One Health approach, and identifying novel LASV vaccine candidates and diagnostic approaches are of paramount importance to prevent a LF pandemic.